Tolebrutinib’s Phase II Study Results Summary:
In completed phase II study, 130 participants with relapsing remitting MS took one of 4 doses of tolebrutinib for 12 weeks either before or after taking placebo for 4 weeks. Compared to the placebo period, treatment with the highest dose of tolebrutinib (same as used in current clinical trials) resulted in 85% to 89% relative reduction in new MS brain lesions.
The most frequently reported side effects in the phase II clinical trial were headaches, and flu-like symptoms.
Or click here to learn more about available clinical trials.